Skip to content

EDESA BIOTECH, INC.: 10-K filed 2017-12-01

What EDESA BIOTECH, INC. reported in its annual report filed 2017-12-01 (fiscal FY 2017): 28 published measures, 78 facts as tagged in accession 0001144204-17-061791.

This filing

Form
10-K (annual report)
Filed
2017-12-01
Fiscal period
fiscal FY 2017
Accession
0001144204-17-061791 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All EDESA BIOTECH, INC. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2017-09-307,720,005USD
At 2016-09-3012,937,804USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2017-09-307,399,058USD
At 2016-09-3012,314,160USD
At 2015-09-308,005,279USD
At 2014-09-3010,464,735USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2017-09-304,570,951USD
At 2016-09-307,416,904USD
At 2015-09-303,955,503USD
At 2014-09-308,768,459USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2016-10-01 to 2017-09-30-5,030,648USD365
2015-10-01 to 2016-09-30-5,026,080USD366
2014-10-01 to 2015-09-30-2,843,029USD365

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2016-10-01 to 2017-09-30-4,699,649USD365
2015-10-01 to 2016-09-30-4,505,629USD366
2014-10-01 to 2015-09-30-4,412,395USD365

Capital expenditure payments

Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.

PeriodValueUnitDays
2016-10-01 to 2017-09-30302,733USD365
2015-10-01 to 2016-09-30402,271USD366
2014-10-01 to 2015-09-30274,589USD365

Revenue

Revenue under this specific accounting concept. A missing value is not zero; filers can use other revenue concepts.

PeriodValueUnitDays
2016-10-01 to 2017-09-30228,287USD365
2015-10-01 to 2016-09-301,271,689USD366
2014-10-01 to 2015-09-30758,689USD365

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2016-10-01 to 2017-09-300USD365
2015-10-01 to 2016-09-307,312,996USD366
2014-10-01 to 2015-09-30106,777USD365

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

PeriodValueUnitDays
2016-10-01 to 2017-09-301,691,660USD365
2015-10-01 to 2016-09-30557,411USD366
2014-10-01 to 2015-09-30122,470USD365

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2017-09-30-45,392,043USD
At 2016-09-30-40,361,395USD

Income tax expense or benefit

Current and deferred income tax expense or benefit for continuing operations. This accounting expense differs from cash taxes paid.

PeriodValueUnitDays
2016-10-01 to 2017-09-30800USD365
2015-10-01 to 2016-09-307,200USD366
2014-10-01 to 2015-09-3036,800USD365

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

PeriodValueUnitDays
At 2017-09-30879,523USD
At 2016-09-30756,114USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2016-10-01 to 2017-09-30115,546USD365
2015-10-01 to 2016-09-30259,379USD366
2014-10-01 to 2015-09-30267,222USD365

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2016-10-01 to 2017-09-30-5,224,546USD365
2015-10-01 to 2016-09-30-4,908,356USD366
2014-10-01 to 2015-09-30-4,338,592USD365

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2017-09-306,758,447USD
At 2016-09-3012,099,655USD

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2017-09-30320,947USD
At 2016-09-30623,644USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2016-10-01 to 2017-09-305,452,833USD365
2015-10-01 to 2016-09-306,180,045USD366
2014-10-01 to 2015-09-305,097,281USD365

Net inventory

Inventory carrying amount after applicable valuation and LIFO reserves. It does not establish realizable selling proceeds or inventory turnover without other inputs.

PeriodValueUnitDays
At 2017-09-3068,114USD
At 2016-09-30249,430USD

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2016-10-01 to 2017-09-301,973,400USD365
2015-10-01 to 2016-09-301,729,445USD366
2014-10-01 to 2015-09-301,029,489USD365

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2017-09-3010,520,096shares
At 2016-09-3010,136,258shares

Accumulated depreciation on property, plant and equipment

Cumulative depreciation, depletion and amortization recorded against property, plant and equipment. It measures cost allocation to date, not physical wear or market value.

PeriodValueUnitDays
At 2017-09-30969,418USD
At 2016-09-30793,057USD

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2016-10-01 to 2017-09-302,944,980USD365
2015-10-01 to 2016-09-303,322,772USD366
2014-10-01 to 2015-09-303,227,545USD365

Depreciation, depletion and amortization

Combined depreciation, depletion and amortization for the period. A noncash allocation of asset cost, not a measure of maintenance spending.

PeriodValueUnitDays
2016-10-01 to 2017-09-30179,322USD365
2015-10-01 to 2016-09-30149,565USD366
2014-10-01 to 2015-09-30159,521USD365

Nonoperating income or expense

Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.

PeriodValueUnitDays
2016-10-01 to 2017-09-30194,698USD365
2015-10-01 to 2016-09-30-110,524USD366
2014-10-01 to 2015-09-301,532,363USD365

Income taxes paid, net

Cash income taxes paid net of refunds during the period. It differs from income tax expense and can reflect prior years and estimated payments.

PeriodValueUnitDays
2016-10-01 to 2017-09-30800USD365
2015-10-01 to 2016-09-307,200USD366
2014-10-01 to 2015-09-3036,800USD365

Proceeds from issuing common stock

Cash received from issuing common stock during the period. It is gross of costs only where the filer reports it so, and it does not include noncash issuances.

PeriodValueUnitDays
2016-10-01 to 2017-09-300USD365
2015-10-01 to 2016-09-306,277,500USD366
2014-10-01 to 2015-09-300USD365

Change in accounts receivable

The cash flow adjustment for the change in receivables during the period. A positive value under this concept means receivables grew and reduced operating cash flow.

PeriodValueUnitDays
2016-10-01 to 2017-09-30-84,573USD365
2015-10-01 to 2016-09-30-71,827USD366
2014-10-01 to 2015-09-30113,917USD365

Change in inventories

The cash flow adjustment for the change in inventories during the period. A positive value under this concept means inventory grew and reduced operating cash flow.

PeriodValueUnitDays
2016-10-01 to 2017-09-30-181,316USD365
2015-10-01 to 2016-09-30-307,850USD366
2014-10-01 to 2015-09-30522,389USD365

Inspect the source

Entity
EDESA BIOTECH, INC. / CIK 0001540159
Captured
2026-09-20T09:17:32.413Z
SEC response SHA-256
0f44de1ccf1eff46a1af17dc21d4a3bb38216bbf46e813f5a136d29e08bfd65d

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001540159.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))